Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China
· Delayed Price · Currency is CNY 15.29
+0.02 (0.13%)
May 14, 2025, 2:45 PM CST
SHA:600535 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 8,475 | 8,468 | 8,636 | 8,606 | 7,898 | 13,505 | Upgrade
|
| Other Revenue | 29.81 | 29.81 | 37.71 | 31.19 | 53.86 | 70.82 | Upgrade
|
| Revenue | 8,504 | 8,498 | 8,674 | 8,637 | 7,952 | 13,576 | Upgrade
|
| Revenue Growth (YoY) | -1.55% | -2.03% | 0.42% | 8.62% | -41.43% | -28.54% | Upgrade
|
| Cost of Revenue | 2,823 | 2,810 | 2,885 | 3,147 | 2,682 | 8,115 | Upgrade
|
| Gross Profit | 5,681 | 5,688 | 5,789 | 5,490 | 5,269 | 5,461 | Upgrade
|
| Selling, General & Admin | 3,371 | 3,334 | 3,326 | 3,267 | 3,339 | 3,215 | Upgrade
|
| Research & Development | 833.75 | 830.07 | 917.27 | 845.34 | 579.53 | 689.33 | Upgrade
|
| Other Operating Expenses | 86.85 | 87.98 | 96.46 | 37.96 | 110.64 | 104.05 | Upgrade
|
| Operating Expenses | 4,301 | 4,252 | 4,348 | 4,149 | 4,027 | 4,073 | Upgrade
|
| Operating Income | 1,380 | 1,436 | 1,441 | 1,341 | 1,243 | 1,388 | Upgrade
|
| Interest Expense | -43.48 | -61.28 | -82.52 | -64.86 | -77.39 | -286.69 | Upgrade
|
| Interest & Investment Income | 102.84 | 91.05 | 107.55 | 107.55 | 1,792 | 241.04 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.07 | -1.07 | -1.23 | -1.61 | 7.27 | 5.58 | Upgrade
|
| Other Non Operating Income (Expenses) | -8.78 | -3.52 | -4.73 | -71.11 | 0 | -11.05 | Upgrade
|
| EBT Excluding Unusual Items | 1,430 | 1,461 | 1,460 | 1,311 | 2,965 | 1,337 | Upgrade
|
| Impairment of Goodwill | -15.88 | -15.88 | - | -151.2 | - | -59.01 | Upgrade
|
| Gain (Loss) on Sale of Investments | -154.92 | -213.45 | -282.81 | -1,125 | -79.88 | 118.21 | Upgrade
|
| Gain (Loss) on Sale of Assets | 9.4 | 2.11 | 0.15 | -4.93 | 41.27 | -5.67 | Upgrade
|
| Asset Writedown | -202.76 | -202.13 | -1.78 | -194.64 | -262.53 | - | Upgrade
|
| Other Unusual Items | 36.78 | 36.78 | 45.51 | -1.96 | 60.04 | 66.91 | Upgrade
|
| Pretax Income | 1,102 | 1,069 | 1,221 | -167.63 | 2,724 | 1,457 | Upgrade
|
| Income Tax Expense | 204.11 | 209.63 | 204.46 | 180.82 | 315.92 | 367.2 | Upgrade
|
| Earnings From Continuing Operations | 898.13 | 859.06 | 1,017 | -348.46 | 2,408 | 1,090 | Upgrade
|
| Minority Interest in Earnings | 76.56 | 96.53 | 54.43 | 84.22 | -48.75 | 36.03 | Upgrade
|
| Net Income | 974.68 | 955.59 | 1,071 | -264.24 | 2,359 | 1,126 | Upgrade
|
| Net Income to Common | 974.68 | 955.59 | 1,071 | -264.24 | 2,359 | 1,126 | Upgrade
|
| Net Income Growth | -11.53% | -10.78% | - | - | 109.51% | 12.43% | Upgrade
|
| Shares Outstanding (Basic) | 1,494 | 1,494 | 1,488 | 1,468 | 1,502 | 1,501 | Upgrade
|
| Shares Outstanding (Diluted) | 1,494 | 1,494 | 1,488 | 1,468 | 1,502 | 1,501 | Upgrade
|
| Shares Change (YoY) | 0.38% | 0.43% | 1.34% | -2.29% | 0.08% | -1.06% | Upgrade
|
| EPS (Basic) | 0.65 | 0.64 | 0.72 | -0.18 | 1.57 | 0.75 | Upgrade
|
| EPS (Diluted) | 0.65 | 0.64 | 0.72 | -0.18 | 1.57 | 0.75 | Upgrade
|
| EPS Growth | -11.87% | -11.16% | - | - | 109.33% | 13.64% | Upgrade
|
| Free Cash Flow | 1,362 | 1,450 | 1,907 | 1,875 | 2,229 | 1,382 | Upgrade
|
| Free Cash Flow Per Share | 0.91 | 0.97 | 1.28 | 1.28 | 1.48 | 0.92 | Upgrade
|
| Dividend Per Share | 0.530 | 0.530 | 0.330 | 0.330 | 0.330 | 0.330 | Upgrade
|
| Dividend Growth | 60.61% | 60.61% | - | - | - | - | Upgrade
|
| Gross Margin | 66.80% | 66.94% | 66.74% | 63.56% | 66.27% | 40.23% | Upgrade
|
| Operating Margin | 16.23% | 16.90% | 16.61% | 15.52% | 15.63% | 10.22% | Upgrade
|
| Profit Margin | 11.46% | 11.24% | 12.35% | -3.06% | 29.66% | 8.29% | Upgrade
|
| Free Cash Flow Margin | 16.01% | 17.06% | 21.98% | 21.71% | 28.04% | 10.18% | Upgrade
|
| EBITDA | 1,749 | 1,832 | 1,946 | 1,774 | 1,648 | 1,927 | Upgrade
|
| EBITDA Margin | 20.57% | 21.56% | 22.43% | 20.54% | 20.72% | 14.20% | Upgrade
|
| D&A For EBITDA | 369.19 | 396.34 | 504.91 | 433.92 | 405.08 | 539.67 | Upgrade
|
| EBIT | 1,380 | 1,436 | 1,441 | 1,341 | 1,243 | 1,388 | Upgrade
|
| EBIT Margin | 16.23% | 16.90% | 16.61% | 15.52% | 15.63% | 10.22% | Upgrade
|
| Effective Tax Rate | 18.52% | 19.62% | 16.74% | - | 11.60% | 25.20% | Upgrade
|
| Revenue as Reported | 8,504 | 8,498 | 8,674 | 8,637 | - | 13,576 | Upgrade
|
Updated Feb 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.